Rhox3f Inhibitors
Rhox3f Inhibitors pertain to a class of chemical compounds that specifically target and inhibit the function of a particular protein encoded by the Rhox3f gene or similar genes within the Rhox cluster. The Rhox gene cluster, which stands for Reproductive Homeobox, is a group of homeobox genes that play a crucial role in the regulation of gene expression during development and cellular differentiation. The Rhox genes are predominantly expressed in reproductive tissues and are implicated in fundamental cellular processes. Inhibitors that focus on the Rhox3f gene product are designed to interact with the protein product at a molecular level, altering its normal function.
The mechanism of action of Rhox3f inhibitors involves the binding to the active site or another relevant structural motif of the Rhox3f protein, which interferes with its ability to bind to DNA and regulate gene expression. This disruption affects the normal transcriptional activity of the protein, leading to a downstream impact on the expression of genes that are under the control of Rhox3f. The design of such inhibitors is based on an intricate understanding of the protein's structure and function, with the aim of achieving high specificity and efficacy in binding. By modulating the activity of Rhox3f, these inhibitors can influence the biological processes that are governed by this gene, which can have various biological implications given the gene's role in cell differentiation and development. The development of Rhox3f inhibitors is a complex process that involves the integration of molecular biology, chemistry, and structural biology disciplines to create molecules that can effectively target and modulate the protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR pathway by binding to FKBP12 and forming a complex that directly inhibits mTORC1. Since the mTOR pathway is crucial for protein synthesis and cellular growth, its inhibition would result in reduced cellular activities, potentially downregulating Rhox3f expression if it's dependent on these cellular states. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, which is upstream of the Akt/mTOR pathway. By inhibiting PI3K, this compound can decrease the activation of downstream proteins, potentially leading to reduced expression or activity of Rhox3f if it is regulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK1, which is part of the MAPK/ERK pathway. This blockade can lead to a decrease in the transcriptional activity of genes that are downstream of this pathway, potentially including Rhox3f if its expression or activity is modulated by MAPK/ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which may reduce the expression of proteins regulated by this stress-activated pathway. If Rhox3f is among those proteins, its functional activity could be decreased as a result of p38 MAPK inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, another member of the MAPK family. Inhibition of JNK can lead to reduced transcriptional activation of certain genes. If Rhox3f expression is controlled by JNK signaling, this compound would lead to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a potent MEK inhibitor, acting on both MEK1 and MEK2, which are upstream of ERK in the MAPK pathway. By inhibiting these kinases, U0126 can decrease the transcription and activity of proteins influenced by this pathway, potentially including Rhox3f. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
WZB117 inhibits glucose transporter 1 (GLUT1), leading to a decrease in glucose uptake. This can result in reduced energy production and an overall downregulation of anabolic processes, which could indirectly influence Rhox3f activity if it is sensitive to alterations in cellular metabolism. | ||||||
Erastin | 571203-78-6 | sc-205677 sc-205677A | 5 mg 50 mg | $365.00 $1582.00 | 1 | |
Erastin specifically targets system x_c^-, which is a cystine/glutamate antiporter. By inhibiting this antiporter, erastin can induce oxidative stress and ferroptosis, potentially leading to reduced expression or activity of Rhox3f if it is susceptible to changes in the redox state of the cell. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can induce cell cycle arrest and apoptosis. If Rhox3f is regulated by ubiquitin-proteasome pathways, bortezomib could lead to its functional inhibition by impacting the degradation of regulatory proteins. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine is an inhibitor of the Hedgehog (Hh) signaling pathway by directly targeting Smoothened. If Rhox3f is downstream of or regulated by the Hh pathway, inhibition by cyclopamine could lead to decreased Rhox3f activity. | ||||||